GLP1s could counteract this
IGF-1 LR3 itself is not FDA-approved for general muscle growth or anti-aging use
If the FDA approves tirzepatide for a new indication that is not weight loss (for example, cardiovascular risk reduction, sleep apnea, or fatty liver disease), and that indication is not explicitly excluded by statute, TRICARE could cover tirzepatide for that indication
Figure 23: Photograph of Professor Graeme Bell in San Francisco taken by Mitsuko Seino in the parking lot of Chiron Corporation, 1984, credit: Accili, Bell
Melanotan-1 is administered via subcutaneous injection into fatty tissue typically the abdomen, thigh, or upper arm using an insulin syringe (2931 gauge, 0.51mL capacity)
Impact on molecular structure and half-life